Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient

Article English OPEN
Schmitt, Laurenz; Schumann, Tamara; Inhoff, Oliver; Löser, Christoph; Rebel, Martin; Dippel, Edgar; (2013)
  • Publisher: S. Karger AG
  • Journal: Case Reports in Dermatology,volume 5,issue 1,pages69-72 (issn: 1662-6567, eissn: 1662-6567)
  • Related identifiers: doi: 10.1159/000350288, pmc: PMC3617885
  • Subject: Zelboraf | Published online: March, 2013 | Melanoma in situ | BRAF inhibitor | Vemurafenib | Melanoma | Wart-like lesions | Dermatology | Side effects | RL1-803 | Eruptive nevi
    mesheuropmc: skin and connective tissue diseases | neoplasms

Background: The BRAF inhibitor vemurafenib is state of the art in therapy of patients with malignant melanoma in non-resectable stage III or stage IV and evidence of oncogenetic BRAF mutation. Multiple cutaneous side effects like rash and keratoacanthoma-like lesions ha... View more
Share - Bookmark